{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:32:45Z","timestamp":1773660765190,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T00:00:00Z","timestamp":1520985600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12957-018-1360-3","type":"journal-article","created":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T10:39:06Z","timestamp":1521023946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer"],"prefix":"10.1186","volume":"16","author":[{"given":"Indika A.","family":"Bandara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minas","family":"Baltatzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudip","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajith K.","family":"Siriwardena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,14]]},"reference":[{"key":"1360_CR1","first-page":"5151","volume":"20","author":"S Mazurek","year":"2000","unstructured":"Mazurek S, Grimm H, Oehmke Weisse G, Teigelkamp S, Eigenbrodt E. Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells. Anticancer Res. 2000;20:5151\u20134.","journal-title":"Anticancer Res"},{"key":"1360_CR2","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.2147\/OTT.S106508","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Hu L, Chen M, Cao W, Chen H, He T. Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies. Onco Targets Ther. 2016;9:4277\u201388.","journal-title":"Onco Targets Ther"},{"key":"1360_CR3","first-page":"3153","volume":"17","author":"E Eigenbrodt","year":"1997","unstructured":"Eigenbrodt E, Basenau D, Holthusen, Mazurek S, Fischer G. Quantification of tumor type M2 pyruvate kinase Tu M2-PK in human carcinomas. Anticancer Res. 1997;17:3153\u20136.","journal-title":"Anticancer Res"},{"key":"1360_CR4","first-page":"2753","volume":"19","author":"F Hugo","year":"1999","unstructured":"Hugo F, Fisher G, Eigenbrodt E. Quantitative detection of tumour M2-PK in serum and plasma. Anticancer Res. 1999;19:2753\u20137.","journal-title":"Anticancer Res"},{"key":"1360_CR5","first-page":"3031","volume":"17","author":"GM Oremek","year":"1997","unstructured":"Oremek GM, Eigenbrodt E, Radle J, Zeuzem S, Seiffert UB. Value of the serum levels of the tumour marker Tu M2-PK in pancreatic cancer. Anticancer Res. 1997;17:3031\u20134.","journal-title":"Anticancer Res"},{"key":"1360_CR6","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/pro.505","volume":"19","author":"V Gupta","year":"2010","unstructured":"Gupta V, Bamezai RN. Human pyruvate kinase M2: a multifunctional protein. Protein Sci. 2010;19:2031\u201344.","journal-title":"Protein Sci"},{"key":"1360_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nature06734","volume":"452","author":"HR Christofk","year":"2008","unstructured":"Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230\u20133.","journal-title":"Nature"},{"key":"1360_CR8","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.biocel.2010.02.005","volume":"43","author":"S Mazurek","year":"2011","unstructured":"Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol. 2011;43:969\u201380.","journal-title":"Int J Biochem Cell Biol"},{"key":"1360_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12943-015-0490-2","volume":"15","author":"N Azoitei","year":"2016","unstructured":"Azoitei N, Becher A, Steinestel K, Rouhi A, Diepold K, Genze F, et al. PKM2 promotes tumor angiogenesis by regulating HIF-1\u03b1 through NF-\u03baB activation. Mol Cancer. 2016;15:3.","journal-title":"Mol Cancer"},{"key":"1360_CR10","doi-asserted-by":"publisher","first-page":"318Y324","DOI":"10.1097\/MPA.0b013e31802ee9c7","volume":"34","author":"KS Goonetilleke","year":"2007","unstructured":"Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW, Siriwardena AK. Diagnostic and prognostic value of tumor M2 pyruvate kinase in peri-ampullary cancer. Pancreas. 2007;34:318Y324.","journal-title":"Pancreas"},{"key":"1360_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/mpa.0b013e3180537237","volume":"35","author":"Y Kumar","year":"2007","unstructured":"Kumar Y, Gurusamy K, Pamecha V, Davidson BR. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis. Pancreas. 2007;35:114\u20139.","journal-title":"Pancreas"},{"key":"1360_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/MPA.0b013e3181bae8ab","volume":"39","author":"MT Joergensen","year":"2010","unstructured":"Joergensen MT, Heegaard NH, Schaffalitzky de Muckadell OB. Comparison of plasma tumor M2-PK and CA19-9 in pancreatic cancer. Pancreas. 2010;39:243\u20137.","journal-title":"Pancreas"},{"key":"1360_CR13","doi-asserted-by":"publisher","first-page":"e0151635","DOI":"10.1371\/journal.pone.0151635","volume":"11","author":"GH Mohammad","year":"2016","unstructured":"Mohammad GH, Olde Damink SW, Malago M, Dhar DK, Pereira SP. Pyruvate kinase M2 and lactate dehydrogenase a are overexpressed in pancreatic cancer and correlate with poor outcome. PLoS One. 2016;11:e0151635.","journal-title":"PLoS One"},{"key":"1360_CR14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3892\/mco.2015.490","volume":"3","author":"H Ogawa","year":"2015","unstructured":"Ogawa H, Nagano H, Konno M, Eguchi H, Koseki J, Kawamoto K, et al. The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer. Mol Clin Oncol. 2015;3:563\u201371.","journal-title":"Mol Clin Oncol"},{"key":"1360_CR15","doi-asserted-by":"publisher","unstructured":"Durczynski A, Skulimowski A, Hogendorf P, Szymanski D, Kumor A et.al. The concentration of D-dimers in portal blood positively correlates with overall survival in patients with non-resectable pancreatic cancer. World J Surg Oncol. 2017;16;15(1):223. \n                    https:\/\/doi.org\/10.1186\/s12957-017-1291-4\n                    \n                  .","DOI":"10.1186\/s12957-017-1291-4"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-018-1360-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12957-018-1360-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-018-1360-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T20:18:06Z","timestamp":1552508286000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-018-1360-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,14]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1360"],"URL":"https:\/\/doi.org\/10.1186\/s12957-018-1360-3","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,14]]},"assertion":[{"value":"3 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the North West Regional Ethics Committee (reference number 10\/H1014\/86). All patients gave their written informed consent for participation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"By giving written informed consent, all patients gave their approval for publication of the results of the study. There are no individually identifiable patient-level data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"56"}}